Pyxis Oncology director granted 45,867 stock options

Pyxis Oncology director Freda C. Lewis-Hall received a stock option award for 45,867 shares of common stock.

Accepted by SEC EDGAR 03/25/2026 - 05:08 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Pyxis Oncology director Freda C. Lewis-Hall received a stock option award for 45,867 shares of common stock. The option has an exercise price of $1.36 per share and expires on March 24, 2036. According to the filing, all 45,867 option shares will vest 100% on the first anniversary of the grant date, if she continues in service through that vesting date. Following this grant, she holds 45,867 stock options directly.

Insider Trade Summary

Grant/Award: 45,867 shares

Grant/Award 1 txn

Insider Lewis-Hall Freda C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	45,867	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 45,867 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Pyxis Oncology (PYXS) report for Freda C. Lewis-Hall?

Pyxis Oncology reported that director Freda C. Lewis-Hall received a stock option award for 45,867 shares of common stock. This is a compensation-related grant, not an open-market share purchase or sale, and is recorded as a derivative transaction on a Form 4.

What are the key terms of Freda C. Lewis-Hall’s stock option grant at Pyxis Oncology (PYXS)?

The option covers 45,867 underlying common shares with an exercise price of $1.36 per share and an expiration date of March 24, 2036. It is reported as a derivative security titled “Stock Option (Right to Buy).”

When do Freda C. Lewis-Hall’s Pyxis Oncology (PYXS) options vest?

All 45,867 option shares will vest 100% on the first anniversary of the March 24, 2026 grant date. Vesting is conditioned on her continued service with the company through the applicable vesting date, as described in the footnote.

Is Freda C. Lewis-Hall’s Form 4 transaction in Pyxis Oncology (PYXS) a buy or a grant?

The transaction is classified as a grant or award acquisition, not an open-market buy. She received 45,867 stock options at a $1.36 exercise price as part of compensation, with no cash purchase of common shares reported in this filing.

How many Pyxis Oncology (PYXS) derivative securities does Freda C. Lewis-Hall hold after this transaction?

After the reported transaction, she holds 45,867 stock options directly, corresponding to 45,867 underlying shares of common stock. The derivative summary in the data shows this grant as the visible derivative position associated with this specific Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lewis-Hall Freda C

(Last) (First) (Middle)

C/O PYXIS ONCOLOGY, INC.

321 HARRISON AVENUE, 11TH FL. SUITE 1

(Street)

BOSTON MASSACHUSETTS 02118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pyxis Oncology, Inc. [ PYXS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.36	03/24/2026		A		45,867		(1)	03/24/2036	Common Stock	45,867	$0	45,867	D

Explanation of Responses:

1. The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

	/s/ Jitendra Wadhane, Attorney-in-Fact for Freda Lewis-Hall	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)